| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd10b5305cfe37e61370b46240c5d976
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c5fa5f189cb6a2e0da3733c346676e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-096 |
| filingDate |
2015-04-21^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29ba7538d25061ac9d7c7fd2e1218918
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3e5665f8143c74d9a9522e7d4bc12f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55b3d803739b0ad5b43a33280d61f16b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e558363caa9c59301d89fc1a45af1f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d281de87a39671b4bb038606936dbb30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9f610fcaf02304e46776f42db3d299c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f5177f8f3240d302749bd040c8075e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2c15673a59d4c3952af0101a2292cba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_368a795df1d92767b1cde378cb8cb0ac |
| publicationDate |
2017-03-08^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3137083-A2 |
| titleOfInvention |
Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts |
| abstract |
The present invention provides polymorphic forms of Vortioxetine of and its pharmaceutically acceptable salts. Specifically the present invention relates to the novel crystalline forms of Vortioxetine or its pharmaceutically acceptable salts. Moreover, the present invention also provides an amorphous form of Vortioxetine hydrobromide and a stable amorphous co-precipitate of Vortioxetine hydrobromide with pharmaceutically acceptable excipients. |
| priorityDate |
2014-04-28^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |